X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (18) 18
hematology (17) 17
humans (16) 16
female (9) 9
male (9) 9
chronic lymphocytic-leukemia (8) 8
treatment outcome (8) 8
aged (7) 7
antineoplastic combined chemotherapy protocols - therapeutic use (7) 7
middle aged (7) 7
hematology, oncology and palliative medicine (6) 6
leukemia, lymphocytic, chronic, b-cell - drug therapy (6) 6
recurrence (6) 6
stem cells (6) 6
transplantation (6) 6
bortezomib (5) 5
ibrutinib (5) 5
oncology (5) 5
retrospective studies (5) 5
survival analysis (5) 5
therapy (5) 5
adult (4) 4
antineoplastic agents - adverse effects (4) 4
antineoplastic combined chemotherapy protocols - adverse effects (4) 4
chemotherapy (4) 4
clinical trials as topic (4) 4
hematopoietic stem cells (4) 4
hemic and lymphatic diseases (4) 4
leukemia, lymphocytic, chronic, b-cell - mortality (4) 4
rituximab (4) 4
salvage therapy - methods (4) 4
aged, 80 and over (3) 3
antibody-drug conjugate (3) 3
antineoplastic agents - administration & dosage (3) 3
antineoplastic agents - therapeutic use (3) 3
antineoplastic combined chemotherapy protocols - administration & dosage (3) 3
article (3) 3
brentuximab vedotin (3) 3
idelalisib (3) 3
immunology (3) 3
immunotherapy (3) 3
lenalidomide (3) 3
leukemia (3) 3
lymphoma, mantle-cell - drug therapy (3) 3
lymphomas (3) 3
mantle cell lymphoma (3) 3
multiple myeloma (3) 3
phase-ii (3) 3
pyrazoles - administration & dosage (3) 3
pyrazoles - adverse effects (3) 3
pyrimidines - administration & dosage (3) 3
pyrimidines - adverse effects (3) 3
t-cell lymphoma (3) 3
alcl (2) 2
animals (2) 2
antibodies, monoclonal - therapeutic use (2) 2
antineoplastic agents - pharmacology (2) 2
b-cell receptor pathway (2) 2
bortezomib - administration & dosage (2) 2
cancer (2) 2
care and treatment (2) 2
chronic lymphatic leukemia (2) 2
chronic lymphocytic leukemia (2) 2
clinical trials and observations (2) 2
cll (2) 2
complications and side effects (2) 2
diarrhea (2) 2
disease (2) 2
disease progression (2) 2
disease-free survival (2) 2
diseases (2) 2
drug administration schedule (2) 2
drug therapy (2) 2
fludarabine (2) 2
immune system diseases (2) 2
immunoconjugates - therapeutic use (2) 2
immunologic factors - therapeutic use (2) 2
initial therapy (2) 2
leukemia, lymphocytic, chronic, b-cell - genetics (2) 2
lymphoma, mantle-cell - therapy (2) 2
marrow-transplantation (2) 2
medicine, research & experimental (2) 2
melphalan (2) 2
monoclonal-antibody (2) 2
non-hodgkins-lymphoma (2) 2
open-label (2) 2
patient outcomes (2) 2
prognosis (2) 2
progression (2) 2
randomized-trial (2) 2
regimen (2) 2
relapse (2) 2
remission induction (2) 2
retreatment (2) 2
survival rate (2) 2
thalidomide - analogs & derivatives (2) 2
thalidomide - therapeutic use (2) 2
toxicity (2) 2
usage (2) 2
abridged index medicus (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Current Opinion in Hematology, ISSN 1065-6251, 09/2019, Volume 26, Issue 6, pp. 421 - 426
PURPOSE OF REVIEWCART cell therapy has changed the treatment landscape for relapsed/refractory aggressive lymphomas. In this article, we review the CART... 
axicabtagene ciloleucel | ZUMA-1 | chimeric antigen receptor T cells | diffuse large B-cell lymphoma | tisagenlecleucel | CILOLEUCEL AXI-CEL | HEMATOLOGY | lisocabtagene maraleucel | Antigen receptors, T cell | Usage | Receptors | Immunotherapy | Lymphomas | Drug therapy | T cells | Methods
Journal Article
Blood, ISSN 0006-4971, 11/2016, Volume 128, Issue 18, pp. 2199 - 2205
Journal Article
Blood, ISSN 0006-4971, 12/2018, Volume 132, Issue 23, pp. 2446 - 2455
Duvelisib (also known as IPI-145) is an oral, dual inhibitor of phosphatidylinositol 3-kinase delta and gamma (PI3K-delta,gamma) being developed for treatment... 
CLL | THERAPY | IDELALISIB | PI3K-DELTA,GAMMA | IBRUTINIB | CHRONIC LYMPHOCYTIC-LEUKEMIA | INHIBITOR | PI3K-GAMMA | COMBINATION | HEMATOLOGY | FLUDARABINE | Clinical Trials and Observations
Journal Article
American Journal of Hematology, ISSN 0361-8609, 11/2018, Volume 93, Issue 11, pp. 1394 - 1401
Journal Article
Clinical Advances in Hematology and Oncology, ISSN 1543-0790, 2015, Volume 13, Issue 1, pp. 44 - 55
Mantle cell lymphoma (MCL) accounts for approximately 6% of all non-Hodgkin lymphomas (NHLs). The median age at diagnosis is 60 to 70 years, although MCL may... 
Bortezomib | Lenalidomide | B-cell receptor pathway | Ibrutinib | Mantle cell lymphoma | Lymphoma, Mantle-Cell - mortality | Lymphoma, Mantle-Cell - diagnosis | Recurrence | Retreatment | Lymphoma, Mantle-Cell - therapy | Prognosis | Humans | Treatment Outcome | Lymphoma, Mantle-Cell - etiology
Journal Article
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 03/2020, Volume 26, Issue 3, pp. S242 - S243
In clinical practice, a hematopoietic progenitor cell (HPC) dose of 2 million CD34+ cells/kg is the desired minimum needed for timely neutrophil and platelet... 
Journal Article
CLINICAL CANCER RESEARCH, ISSN 1078-0432, 07/2019, Volume 25, Issue 14, pp. 4264 - 4270
Purpose: Clinical trials of venetoclax reported negligible rates of clinical tumor lysis syndrome (TLS) in patients with chronic lymphocytic leukemia (CLL)... 
ONCOLOGY | CHRONIC LYMPHOCYTIC-LEUKEMIA | OUTCOMES
Journal Article
Frontiers in Oncology, ISSN 2234-943X, 2013, Volume 3
Peripheral T-cell lymphomas comprise a heterogeneous group of NHLs, with different clinical and biological behaviors, but with a common denominator of poor... 
Brentuximab | Bortezomib | Alisertib | PTCL | Zanolimumab | ALCL | Romidepsin | Pralatrexate | Brentuximab vedotin | Lenalidomide | T-cell lymphoma
Journal Article
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2016, Volume 23, Issue 3, pp. S198 - S199
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 4554 - 4554
Abstract Background: Autologous stem cell transplantation (ASCT) is increasingly offered to older patients with multiple myeloma (MM) based on clinical trials... 
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 2154 - 2154
Abstract Background: A regimen of escalating doses of thalidomide, in combination with bortezomib and high dose melphalan (Mel/Vel/Thal) was evaluated as a... 
Journal Article
Best Practice & Research: Clinical Haematology, ISSN 1521-6926, 2012, Volume 25, Issue 2, pp. 201 - 210
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 3383 - 3383
Abstract Background: TA-TMA is a life-threatening complication of hematopoietic cell transplantation (HCT), usually manifested as a combination of non-immune... 
Journal Article
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2016, Volume 22, Issue 11, pp. 2047 - 2055
Highlights • Haploidentical and unrelated donor transplantation have similar risks of acute and chronic GvHD. • Haploidentical and unrelated donor recipients... 
Hematology, Oncology and Palliative Medicine | Haploidentical transplantation | Unrelated donor transplantation | Post-transplantation cyclophosphamide | TOTAL-BODY IRRADIATION | VIRUS-INFECTION | PHASE-II | ACUTE MYELOID-LEUKEMIA | IMMUNOLOGY | VERSUS-HOST-DISEASE | SIBLING DONORS | TRANSPLANTATION | HIGH-RISK | POSTTRANSPLANTATION CYCLOPHOSPHAMIDE | LYMPHOPROLIFERATIVE DISORDERS | HEMATOLOGY | T-CELLS | Hematologic Neoplasms - therapy | Peripheral Blood Stem Cell Transplantation - adverse effects | Peripheral Blood Stem Cell Transplantation - methods | Hematologic Neoplasms - mortality | Humans | Middle Aged | Male | Bone Marrow Transplantation - methods | Transplantation, Haploidentical - mortality | Cyclophosphamide - therapeutic use | Young Adult | Adult | Female | Unrelated Donors | Hematologic Neoplasms - complications | Virus Activation | Peripheral Blood Stem Cell Transplantation - mortality | Graft Survival | Treatment Outcome | Bone Marrow Transplantation - mortality | Survival Analysis | Transplantation, Haploidentical - adverse effects | Bone Marrow Transplantation - adverse effects | Graft vs Host Disease - prevention & control | Aged | Chimerism | Premedication | Bone marrow | Transplantation | Comparative analysis | Hematopoietic stem cells | Stem cells | Patient outcomes | Oncology, Experimental | Cytomegalovirus infections | Research | Cancer
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.